Dihydroergotamine Mesylate

Junevity首曝"逆转衰老"siRNA数据 2026年6月3日，美国衰老协会（AGE）2026年年会的舞台上，联合创始人 Dr. Janine Sengstack 宣布了生物医药界等待多年的数据—— 一项 siRNA 疗法，在糖尿病小鼠体内，让整个衰老相关基因网络的表达谱，恢复到了健康小鼠的水平。 不是修复一两个基因，是整个网络。 只打一个靶点，为什么够了？ 传统认知里，衰老是数百个基因表达紊乱的叠加结果。要"逆转衰老"，似乎必须同时干预很多位点——就像同时修补一张漏水的管道网络，哪根都要堵。 Junevity 的逻辑完全不一样。核心假说来自 UCSF 研究团队 2017 年的论文：也许存在一个"衰老主控开关"，上游调控着大部分与衰老相关基因的异常表达。沉默这一个转录因子，就能让整个网络复位。 他们把这个发现和筛选平台命名为 RESET——用 RNA-seq、CRISPR Perturb-seq、计算建模和机器学习找靶点，用 siRNA 精准沉默。 这个假说在 2022 年 preprint 和 2026 年 PNAS 同行评审论文中都得到验证。PNAS 论文（2026年1月12日发表）明确：单个转录因子调控，足以在人细胞衰老模型中逆转多个衰老标志（蛋白质稳态、线粒体功能、细胞衰老），同时不引发细胞脱分化或致癌程序。 年会上的体内数据：肝再生、血糖改善 这次 AGE 年会（6月2–5日，美国犹他州普罗沃）补充了一个关键缺失环节——活体（in vivo）数据。 在小鼠体内，用 GalNAc 偶联的肝靶向 siRNA 沉默一个衰老相关转录因子后，年老小鼠的肝脏出现了显著 rejuvenate 表型： • 肝脏脂肪变性（steatosis）逆转 • 肝纤维化（fibrosis）减轻 • 糖耐量（glucose tolerance）改善 换句话说，不仅是细胞层面的基因网络恢复，更是器官功能的实际改善。 GalNAc：siRNA 走进肝脏的钥匙 siRNA 疗法有个老问题：怎么让药物精准到达目标组织。 Junevity 使用的是 GalNAc 偶联技术。GalNAc 是肝脏靶向配体，能让 siRNA 分子"认路"进入肝细胞。这项技术已通过 inclisiran、givosiran 等获批药物积累了充分的安全性数据。 siRNA 进入细胞后，会特异性降解目标 mRNA，阻止对应蛋白的翻译。效果是暂时性的，给药后可重复。相比永久改变 DNA 的基因编辑，siRNA 在可逆性和安全性上更有余地。 候选分子 JUN_01：每半年给药一次 Junevity 的主导候选分子 JUN_01 已推进到非人灵长类研究阶段。 在临床前研究中，JUN_01 显示：血糖降低、胰岛素敏感性改善、体重减轻且维持去脂体重——同时借助 siRNA 的安全性优势，给药间隔可达每6个月一次。 该靶点是 Junevity RESET 平台从人类疾病数据、遗传学关联和机器学习中挖掘出的一个全新、保密靶点，作为慢性代谢功能障碍、胰岛素信号和食欲的主要调节因子。 更值得关注的是 JUN_01 与 GLP-1 类药物的协同潜力——公司表示它既可作为单药，也可与 GLP-1 联用，有望实现更低的给药剂量或更低的给药频率。 Junevity 正在推进 JUN_01 的首次人体试验，目标时间是 2026 年下半年（second half of 2026）。从 2017 年 UCSF 的高风险 PhD 项目，到 2026 年进入临床，这个团队用了不到十年。 不只是代谢——神经退行性疾病也在管线内 除了 JUN_01，Junevity 的管线还覆盖： • 肥胖 • 神经退行性疾病（含帕金森病） 公司长期愿景是：用 siRNA 细胞重编程技术，恢复所有与复杂疾病相关组织的基因网络，从而延长健康寿命（healthspan）。 融资情况：Seed 轮已扩至 2000 万美元 2025年12月，Junevity 宣布追加 1000 万美元融资，Seed 轮总规模达到 2000 万美元。本轮由 Goldcrest Capital 和 Godfrey Capital 领投，资金将支持 JUN_01 推进 IND-enabling 研究和初始临床研究。 CEO 身份：John Hoekman 补充说明公司领导层：Junevity 联合创始人兼 CEO 是 John Hoekman，他此前联合创立了 Impel Pharmaceuticals，将自己在华盛顿大学的博士研究转化为 FDA 批准的重磅偏头痛药物 Trudhesa。这也是为什么 Junevity 创始团队被描述为"连续创业者"——有成功退出的经验。 这扇门已经被推开 衰老能不能被"逆转"，这个问题在生物医药界争议了很久。 传统观点认为，衰老是积累性损伤，不可逆。近年研究表明，衰老也许是一种可调控的基因网络异常状态。一旦找到正确的干预节点，系统可以恢复。 Junevity 用 siRNA 做到了在小鼠体内证明这一点。 当然，从小鼠到人体还有很长的路——安全性的完整验证、人体药效学数据、长期随访，每一步都需要时间。但不管最终结果如何，这个方向已经被验证可行。 2026 年，可能是"逆转衰老"从学术走向临床的转折点。

Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update. Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "Our focus in the first quarter was on our work to secure a strategic transaction for our company and our shareholders. We are pleased to report that on March 26th we announced entering into a merger agreement with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using its proprietary MitoXcel™ platform. We also secured aggregate gross proceeds of $1 million from a private placement of preferred stock from an affiliate of Eos. Separate from the preferred stock, our common stockholders will receive approximately 6% interest in the new combined company without dilution from the preferred stock." Proposed Merger with Eos SENOLYTIX As previously reported, on March 26, 2026, the Company entered into an agreement (the "Merger Agreement") and plan of merger (the "Merger") with Eos SENOLYTIX, Inc. ("Eos"). The proposed Merger is anticipated to close in the third quarter of 2026, subject to customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company. In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of $1.0 million. Additional information about the Merger Agreement was previously disclosed on a Current Report on Form 8-K filed with the SEC on March 27, 2026. Pulmatrix Seeks to Out-license or Monetize its Clinical Assets iSPERSE™ Technology iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases. As of March 31, 2026, Pulmatrix's patent portfolio related to iSPERSE™ included approximately 146 granted patents, 18 of which are U.S.-granted patents, plus approximately 48 pending patent applications in the U.S. and other jurisdictions. PUR1900 PUR1900, has been approved to proceed to a Phase 3 in India conducted by our partner Cipla. This is the Company's inhaled iSPERSE™ formulation of the antifungal drug itraconazole being investigated for various indications. The Company and its partner, Cipla, wound down a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development outside the United States, and in 2025 completed their Phase 2 study in India, published positive results and has been approved by India's Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026. Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States should Cipla successfully market PUR1900 outside the United States. Within the United States, the Company and Cipla share the rights 50/50 and will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need. PUR3100 PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine ("DHE") engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine. The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously ("IV") administered DHE dose group. PUR1800 PUR1800 is a Narrow Spectrum Kinase Inhibitor ("NSKI"), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease ("AECOPD"). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases. In 2024, Pulmatrix published an abstract titled "Ex vivo evaluation of the potential for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis". First Quarter 2026 Financial Results Research and development expenses were less than $0.1 million for both the three months ended March 31, 2026, and 2025. All clinical development is currently on hold while the Company works to license or monetize our clinical assets. General and administrative expenses decreased approximately $0.5 million to $1.3 million for the three months ended March 31, 2026, compared to $1.8 million for the three months ended March 31, 2025. The decrease was primarily due to higher costs incurred in the three months ended March 31, 2025, related to the preparation and filing of a registration statement on Form S-4 and amendments thereto with the SEC. The Company's total cash and cash equivalents balance as of March 31, 2026, was $3.3 million, compared to $4.1 million as of December 31, 2025. The Company's unaudited financial statements were prepared assuming that the Company will continue as a going concern within one year after the date such financial statements are issued. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations at least through the anticipated closing of the proposed Merger with Eos. About Pulmatrix, Inc. Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company's inhaled product candidates please visit: . About Eos SENOLYTIX, Inc. Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos's lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and (2) the profound elimination of senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects. Extensive preclinical studies suggest the MitoXcel™ platform may be a broad gerotherapeutic that improves body composition, increasing lean muscle mass, and enhancing physical function in aging animals. By targeting fundamental processes driving aging and aging-related diseases, Eos SENOLYTIX is pursuing a unique therapeutic opportunity to intervene in the aging process in ways that were once thought impossible. Eos SENOLYTIX is headquartered in Houston, Texas and operates within the broader SENOTHERAPEUTIX / GEROTHERAPEUTIX group of longevity companies, which focuses on developing therapeutics targeting fundamental drivers of aging to improve healthspan and lifespan. For more information, visit . Forward-Looking Statements Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management and include, but are not limited to, the use of proceeds from the private placement and conversion of the Series B Preferred Stock. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company's ability to divest its clinical assets on terms favorable to the Company, or at all, the Company's ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company's ability to continue as a going concern, the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: Chuck Padala Managing Director LifeSci Advisors 646-627-8390 [email protected] SOURCE Pulmatrix Inc. 21% more press release views with Request a Demo